RMC No. 63-2023 revokes prior CDC tax rulings and denies Clark locator 5% gross income tax incentives to CDC under the CREATE Law framework.

Businesses dealing with Clark Development Corporation, government-owned and controlled corporations, and tax teams handling Clark Special Economic Zone transactions should immediately review any tax treatment that relied on BIR Ruling Nos. 038-2001 and 046-1995. RMC No. 63-2023 revokes those rulings and confirms that CDC should not be treated like a registered Clark locator entitled to the five percent (5%) preferential tax on gross income earned in lieu of local and national internal revenue taxes.

What Changed Under RMC No. 63-2023

RMC No. 63-2023 revokes BIR Ruling Nos. 038-2001 and 046-1995. Those earlier rulings had treated Clark Development Corporation, or CDC, as a business enterprise because it performed activities proprietary in nature. On that basis, CDC had been considered entitled to the same privileges as other enterprises operating within the Clark Special Economic Zone, including the five percent (5%) preferential tax rate based on gross income earned, in lieu of local and national internal revenue taxes.

The new rule is that CDC cannot claim the fiscal and non-fiscal incentives that are exclusively granted to registered business enterprises. The BIR’s position is that CDC is a government-owned and controlled corporation entrusted with regulatory functions, and not a business enterprise operating on equal footing with Clark Special Economic Zone locators.

This matters because the distinction between an investment promotion agency and a registered business enterprise is now central under the CREATE Law framework. RMC No. 63-2023 treats CDC as an investment promotion agency, not as a registered business enterprise. As a result, CDC’s income is subject to income tax under Section 27(C) of the Tax Code, rather than the special five percent (5%) gross income tax regime available to qualified registered business enterprises.

Why the BIR Rejected the Prior CDC Tax Treatment

The revoked rulings treated CDC’s proprietary activities as sufficient basis to give it the same fiscal treatment as enterprises operating in the Clark Special Economic Zone. RMC No. 63-2023 reverses that approach by focusing on CDC’s legal character and statutory role.

A government-owned and controlled corporation is described in the circular as an agency organized as a stock or nonstock corporation, vested with functions relating to public needs, owned by the Government of the Republic of the Philippines directly or through instrumentalities, and, in the case of stock corporations, owned at least by a majority of outstanding capital stock. CDC is a stock corporation vested with functions relating to public needs and owned by the Government through the Bases Conversion and Development Authority.

CDC was established to manage the Clark Special Economic Zone. Its functions include operating, administering, managing, and developing the Clark Special Economic Zone; registering, regulating, and supervising enterprises in the zone; coordinating with local government units and exercising general supervision over the development plans, activities, and operations of the zone; constructing, acquiring, owning, leasing, operating, and maintaining facilities and infrastructure; and creating, operating, or contracting agencies, functional units, or offices of authority as necessary.

Because those functions are regulatory and administrative, the BIR concluded that CDC does not stand on the same footing as private business enterprises registered within the Clark Special Economic Zone. The key legal consequence is that CDC should be taxed as a GOCC, not as a Clark locator enjoying the five percent (5%) gross income tax incentive.

Who Is Most Affected

The most directly affected taxpayer is Clark Development Corporation. Its prior ability to invoke the revoked BIR rulings as basis for enjoying the five percent (5%) preferential gross income tax treatment is removed by RMC No. 63-2023.

The ruling also matters to companies doing business with CDC, including Clark locators, suppliers, contractors, service providers, and entities that must determine withholding tax, invoice treatment, accounting classification, and tax reporting for transactions involving CDC. Corporate accountants and CFOs should not assume that CDC transactions are covered by the same tax incentive treatment applicable to registered Clark enterprises.

Other government-owned and controlled corporations and investment promotion agencies should also take note. RMC No. 63-2023 emphasizes that an entity cannot be treated as both an investment promotion agency and a registered business enterprise for purposes of CREATE Law incentives. Under the circular, investment promotion agencies and registered business enterprises are separate and distinct entities with different purposes and functions.

CREATE Law Distinction: IPA Versus RBE

RMC No. 63-2023 relies heavily on the CREATE Law framework. Under the circular’s discussion, registered business enterprises are individual taxpayers, partnerships, corporations, Philippine branches of foreign corporations, or other entities organized under Philippine law and registered with an investment promotion agency, whether inside or outside economic zones, that are granted fiscal and non-fiscal incentives to the extent of their approved registered project or activity under the Strategic Investment Priority Plan.

Investment promotion agencies, by contrast, are government entities created by law, executive order, decree, or other issuance, in charge of promoting investments, granting and administering fiscal or non-fiscal incentives, and overseeing the operations of different economic zones and freeports. CDC falls within this latter category.

The practical point for tax compliance is straightforward: the incentives administered by an investment promotion agency are not automatically available to the agency itself. RMC No. 63-2023 states that, while CDC performs functions proprietary in nature, it is classified as an investment promotion agency and not as a registered business enterprise. Therefore, CDC cannot avail of fiscal and non-fiscal incentives exclusively granted to registered business enterprises.

Key Compliance Requirements and Effective Consequences

Tax teams should treat the revocation as immediately relevant to ongoing compliance positions involving CDC. The circular expressly states that BIR Ruling Nos. 038-2001 and 046-1995 are revoked and invalidated, and that all revenue issuances inconsistent with RMC No. 63-2023 are deemed repealed.

For accounting and tax reporting, the most important compliance adjustment is to stop relying on the revoked rulings as authority for treating CDC as entitled to the five percent (5%) preferential tax rate based on gross income earned. The applicable tax treatment identified in the circular is income tax under Section 27(C) of the Tax Code.

The circular also states that the revocation is without prejudice to Section 246 of the Tax Code. This reference is important because Section 246 concerns non-retroactivity of rulings in appropriate cases. However, RMC No. 63-2023 does not provide a separate deadline, transition period, special filing procedure, or numerical threshold apart from the five percent (5%) preferential gross income tax treatment being disallowed for CDC.

Penalties for Non-Compliance

RMC No. 63-2023 does not prescribe a special penalty, surcharge, or fine specific to the revocation of BIR Ruling Nos. 038-2001 and 046-1995. The compliance risk is instead practical and assessment-driven: taxpayers and withholding agents that continue to rely on an invalidated ruling may face tax exposure if the resulting tax treatment is inconsistent with the BIR’s current position.

Because the circular does not create a separate penalty table, businesses should avoid overstating the rule. The safer approach is to document the change, review affected transactions, and confirm whether prior tax positions involving CDC need to be revisited in light of the BIR’s express revocation.

Practical Steps for CFOs, Accountants, and Clark Businesses

First, identify all existing and recurring transactions with Clark Development Corporation. Review invoices, contracts, payment processes, withholding tax treatment, and tax assumptions that may have treated CDC as equivalent to a Clark registered business enterprise.

Second, update internal tax memoranda and accounting policies. Any reference to BIR Ruling No. 038-2001 or BIR Ruling No. 046-1995 as authority for CDC’s entitlement to the five percent (5%) gross income tax incentive should be removed or marked as revoked.

Third, distinguish between CDC as an investment promotion agency and Clark locators as registered business enterprises. This distinction is critical for CREATE Law compliance, especially for companies searching for guidance on CDC tax treatment, Clark Development Corporation income tax, Clark locator incentives, five percent gross income earned tax, and investment promotion agency versus registered business enterprise rules.

Fourth, consult counsel before revising prior filings or taking a position on Section 246 non-retroactivity. RMC No. 63-2023 expressly refers to Section 246, but it does not automatically resolve every historical reliance issue. The appropriate treatment may depend on the taxpayer, the period involved, the transaction documents, and the specific tax position previously taken.

How Ablola, Saribong & Gueco Can Help

RMC No. 63-2023 is a reminder that BIR rulings can be revoked when the BIR reconsiders the legal character of the taxpayer or the incentive regime being applied. For businesses in Clark, companies contracting with CDC, and CFOs managing CREATE Law incentive compliance, the issue is not merely academic. It can affect tax classification, withholding treatment, financial reporting, and audit exposure.

Ablola, Saribong & Gueco advises corporations, business owners, accountants, and in-house legal teams on BIR rulings, tax assessments, CREATE Law incentives, withholding tax compliance, and transactions involving government-owned and controlled corporations. For assistance in reviewing your company’s exposure under RMC No. 63-2023 or other BIR issuances, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *